BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26521930)

  • 1. Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.
    Ghali JR; Holdsworth SR; Kitching AR
    Curr Med Chem; 2015; 22(38):4341-65. PubMed ID: 26521930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
    Hu Y; Shen F; Crellin NK; Ouyang W
    Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17C/IL-17 Receptor E Signaling in CD4
    Krohn S; Nies JF; Kapffer S; Schmidt T; Riedel JH; Kaffke A; Peters A; Borchers A; Steinmetz OM; Krebs CF; Turner JE; Brix SR; Paust HJ; Stahl RAK; Panzer U
    J Am Soc Nephrol; 2018 Apr; 29(4):1210-1222. PubMed ID: 29483158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.
    Yamagata T; Skepner J; Yang J
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):405-14. PubMed ID: 26358867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
    Toussirot E
    Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T helper type 17 cells in immune-mediated glomerular disease.
    Krebs CF; Schmidt T; Riedel JH; Panzer U
    Nat Rev Nephrol; 2017 Oct; 13(10):647-659. PubMed ID: 28781371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
    Patel DD; Lee DM; Kolbinger F; Antoni C
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.
    Wright JF; Bennett F; Li B; Brooks J; Luxenberg DP; Whitters MJ; Tomkinson KN; Fitz LJ; Wolfman NM; Collins M; Dunussi-Joannopoulos K; Chatterjee-Kishore M; Carreno BM
    J Immunol; 2008 Aug; 181(4):2799-805. PubMed ID: 18684971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
    Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
    Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Th17 cells in autoimmune diseases.
    Yang J; Sundrud MS; Skepner J; Yamagata T
    Trends Pharmacol Sci; 2014 Oct; 35(10):493-500. PubMed ID: 25131183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of either IL-17A or IL-17F is sufficient to inhibit house dust mite induced allergic asthma in mice.
    Chenuet P; Fauconnier L; Madouri F; Marchiol T; Rouxel N; Ledru A; Mauny P; Lory R; Uttenhove C; van Snick J; Iwakura Y; di Padova F; Quesniaux V; Togbe D; Ryffel B
    Clin Sci (Lond); 2017 Oct; 131(20):2533-2548. PubMed ID: 29026003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of IL-17 in psoriasis.
    Malakouti M; Brown GE; Wang E; Koo J; Levin EC
    J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
    Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
    BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasticity and heterogeneity of Th17 in immune-mediated kidney diseases.
    Krebs CF; Panzer U
    J Autoimmun; 2018 Feb; 87():61-68. PubMed ID: 29275837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
    von Stebut E; Boehncke WH; Ghoreschi K; Gori T; Kaya Z; Thaci D; Schäffler A
    Front Immunol; 2019; 10():3096. PubMed ID: 32010143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
    Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
    J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of IL-17A in inflammatory immune responses and host defense against pathogens.
    Iwakura Y; Nakae S; Saijo S; Ishigame H
    Immunol Rev; 2008 Dec; 226():57-79. PubMed ID: 19161416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 in systemic lupus erythematosus: A comprehensive review.
    Li D; Guo B; Wu H; Tan L; Chang C; Lu Q
    Autoimmunity; 2015; 48(6):353-61. PubMed ID: 25894789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and functions of IL-17 signaling in renal autoimmune diseases.
    Schmidt T; Luebbe J; Paust HJ; Panzer U
    Mol Immunol; 2018 Dec; 104():90-99. PubMed ID: 30448610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.